NBY Annual Accounts Receivable
$759.00 K
-$1.21 M-61.53%
01 December 2023
Summary:
As of January 20, 2025, NBY annual accounts receivable is $759.00 thousand, with the most recent change of -$1.21 million (-61.53%) on December 1, 2023. During the last 3 years, it has fallen by -$347.00 thousand (-31.37%). NBY annual accounts receivable is now -79.76% below its all-time high of $3.75 million, reached on December 31, 2009.NBY Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NBY Quarterly Accounts Receivable
$704.00 K
+$157.00 K+28.70%
01 September 2024
Summary:
As of January 20, 2025, NBY quarterly accounts receivable is $704.00 thousand, with the most recent change of +$157.00 thousand (+28.70%) on September 1, 2024. Over the past year, it has dropped by -$212.00 thousand (-23.14%). NBY quarterly accounts receivable is now -81.23% below its all-time high of $3.75 million, reached on December 31, 2009.NBY Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NBY Accounts Receivable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -61.5% | -23.1% |
| 3 y3 years | -31.4% | -73.2% |
| 5 y5 years | -77.6% | -73.2% |
NBY Accounts Receivable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -61.5% | at low | -73.2% | +28.7% |
| 5 y | 5-year | -61.5% | at low | -73.2% | +28.7% |
| alltime | all time | -79.8% | -81.2% |
NovaBay Pharmaceuticals Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $704.00 K(+28.7%) |
| June 2024 | - | $547.00 K(-25.5%) |
| Mar 2024 | - | $734.00 K(-3.3%) |
| Dec 2023 | $759.00 K(-61.5%) | $759.00 K(-17.1%) |
| Sept 2023 | - | $916.00 K(-65.1%) |
| June 2023 | - | $2.62 M(+42.9%) |
| Mar 2023 | - | $1.83 M(-7.0%) |
| Dec 2022 | $1.97 M(+18.3%) | $1.97 M(-7.5%) |
| Sept 2022 | - | $2.13 M(+94.3%) |
| June 2022 | - | $1.10 M(-52.3%) |
| Mar 2022 | - | $2.30 M(+37.9%) |
| Dec 2021 | $1.67 M(+50.8%) | $1.67 M(+97.9%) |
| Sept 2021 | - | $843.00 K(-31.6%) |
| June 2021 | - | $1.23 M(+18.7%) |
| Mar 2021 | - | $1.04 M(-6.1%) |
| Dec 2020 | $1.11 M(+3.8%) | $1.11 M(-1.2%) |
| Sept 2020 | - | $1.12 M(-19.6%) |
| June 2020 | - | $1.39 M(+46.1%) |
| Mar 2020 | - | $952.00 K(-10.7%) |
| Dec 2019 | $1.07 M(-68.5%) | $1.07 M(-29.2%) |
| Sept 2019 | - | $1.50 M(-2.0%) |
| June 2019 | - | $1.54 M(-36.8%) |
| Mar 2019 | - | $2.43 M(-28.2%) |
| Dec 2018 | $3.38 M(-6.7%) | $3.38 M(+29.6%) |
| Sept 2018 | - | $2.61 M(+29.1%) |
| June 2018 | - | $2.02 M(-9.0%) |
| Mar 2018 | - | $2.23 M(-38.7%) |
| Dec 2017 | $3.63 M | $3.63 M(+62.7%) |
| Sept 2017 | - | $2.23 M(-38.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| June 2017 | - | $3.60 M(+54.5%) |
| Mar 2017 | - | $2.33 M(+10.0%) |
| Dec 2016 | $2.12 M(+295.5%) | $2.12 M(+2.0%) |
| Sept 2016 | - | $2.08 M(+39.5%) |
| June 2016 | - | $1.49 M(-0.5%) |
| Mar 2016 | - | $1.50 M(+179.3%) |
| Dec 2015 | $536.00 K(+96.3%) | $536.00 K(-1.3%) |
| Sept 2015 | - | $543.00 K(+39.6%) |
| June 2015 | - | $389.00 K(+37.5%) |
| Mar 2015 | - | $283.00 K(+3.7%) |
| Dec 2014 | $273.00 K(-65.2%) | $273.00 K(-25.0%) |
| Sept 2014 | - | $364.00 K(-17.3%) |
| June 2014 | - | $440.00 K(+69.2%) |
| Mar 2014 | - | $260.00 K(-66.8%) |
| Dec 2013 | $784.00 K(-16.9%) | $784.00 K(+188.2%) |
| Sept 2013 | - | $272.00 K(+142.9%) |
| June 2013 | - | $112.00 K(-87.8%) |
| Mar 2013 | - | $916.00 K(-2.9%) |
| Dec 2012 | $943.00 K(>+9900.0%) | $943.00 K(+648.4%) |
| Sept 2012 | - | $126.00 K(+1300.0%) |
| June 2012 | - | $9000.00(-99.1%) |
| Mar 2012 | - | $1.01 M(>+9900.0%) |
| Dec 2011 | $3000.00(-99.4%) | $3000.00(-99.8%) |
| Sept 2011 | - | $1.82 M(-48.8%) |
| June 2011 | - | $3.57 M(>+9900.0%) |
| Mar 2011 | - | $0.00(-100.0%) |
| Dec 2010 | $500.00 K(-86.7%) | $500.00 K(-86.7%) |
| Dec 2009 | $3.75 M(>+9900.0%) | $3.75 M(>+9900.0%) |
| Dec 2008 | $0.00 | $0.00 |
FAQ
- What is NovaBay Pharmaceuticals annual accounts receivable?
- What is the all time high annual accounts receivable for NovaBay Pharmaceuticals?
- What is NovaBay Pharmaceuticals annual accounts receivable year-on-year change?
- What is NovaBay Pharmaceuticals quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for NovaBay Pharmaceuticals?
- What is NovaBay Pharmaceuticals quarterly accounts receivable year-on-year change?
What is NovaBay Pharmaceuticals annual accounts receivable?
The current annual accounts receivable of NBY is $759.00 K
What is the all time high annual accounts receivable for NovaBay Pharmaceuticals?
NovaBay Pharmaceuticals all-time high annual accounts receivable is $3.75 M
What is NovaBay Pharmaceuticals annual accounts receivable year-on-year change?
Over the past year, NBY annual accounts receivable has changed by -$1.21 M (-61.53%)
What is NovaBay Pharmaceuticals quarterly accounts receivable?
The current quarterly accounts receivable of NBY is $704.00 K
What is the all time high quarterly accounts receivable for NovaBay Pharmaceuticals?
NovaBay Pharmaceuticals all-time high quarterly accounts receivable is $3.75 M
What is NovaBay Pharmaceuticals quarterly accounts receivable year-on-year change?
Over the past year, NBY quarterly accounts receivable has changed by -$212.00 K (-23.14%)